A Complete And Practical Analysis Packed With Facts, Figures, Forecasts And Product/Competitive Assessments

Covering POC tests for Blood Glucose | Cholesterol | Cardiac Markers | Coagulation | Infectious Disease | Blood | Cancer | Urinalysis | Pregnancy & Fertility | Drugs of Abuse

The Point Of Care Diagnostics market was worth US$13.7 billion in 2010 and rose by 3% compared with 2009. The market has historically risen at a much stronger rate and this slowdown was due to a stagnation for blood glucose testing due to weak pricing and volumes in the US. Excluding blood glucose, the market rose by 7% in 2010, driven by demand for cardiovascular testing products.

Annual market growth of 8 to 9% is predicted to 2016 due to a growing interest in the adoption of Point Of Care technologies by both healthcare providers and consumers, and the introduction of new products that enable POC testing for more applications, enhance ease-of-use and improve on the accuracy of current products.

M&A activity increases as big players diversify and manoeuvre for position Merger and acquisition activity has increased significantly in recent years, with around 15 key transactions taking place since the beginning of 2009. This industry consolidation is changing the dynamics of the market. In particular, Alere has reinforced its dominance of several product segments, acquiring a leading position in the European drug testing market by purchasing Concateno and a strong position in emerging regions with South Korean manufacturer, Standard Diagnostics. Heightened M&A activity is also increasing investment in new technology as companies with more financial clout enter the sector, although potentially to the detriment of smaller companies.

Key Features:

Includes Market Forecasts to 2016

Reasons to Buy:

Use this report to:

For more information visit http://www.researchandmarkets.com/research/6487ab/point_of_care_diag

Source: Espicom Business Intelligence Ltd